source
- BMS reports fatal septic pneumonia in MS patient during CAR T trial of zolacabtagene autoleucelBMS disclosed that a participant in its Phase 1 Breakfree-2 study of the CAR T cell therapy zolacabtagene autoleucel died from septic pneumonia. The patient, who had highly active relapsing multip…
- Roche signs up to $813M deal with Zymeworks for preclinical trispecific T cell engagerRoche announced a partnership with Zymeworks that includes an upfront payment of $55 million for worldwide rights to a trispecific T cell engager currently in preclinical development. The agreemen…